Spero Therapeutics, Inc. (SPRO) - Form 8-K Summary
Business Context and Reporting Period
Spero Therapeutics, Inc., a Delaware corporation, filed this Current Report on Form 8-K on March 26, 2026. The filing announces the results of operations and financial condition for the fourth quarter and full year ended December 31, 2025. The company is headquartered in Cambridge, Massachusetts, and its common stock trades on The Nasdaq Global Select Market under the symbol SPRO.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This 8-K serves as a notification that a press release containing these details has been issued and is attached as Exhibit 99.1. The document explicitly states that the information in the press release is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Material Changes
The filing does not contain specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for comparative financial analysis.
Guidance, Outlook, and Risks
This specific 8-K text does not include management commentary, forward-looking guidance, risk factors, or contingencies. Such information is contained within the press release furnished as Exhibit 99.1. The filing notes that the press release information is not incorporated by reference into other SEC filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual Q4 and full-year 2025 financial figures.
- Verify the company's cash runway and burn rate, as these are not disclosed in the 8-K text.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm the status of the company's debt obligations and liquidity position from the full financial statements.